To examine the prevalence and correlates of infection with herpes simplex virus type 2 (HSV-2) among sexually transmitted disease (STD) clinic attenders, we studied the prevalence of antibodies to HSV-2 and their association with risk behaviour. Methods Data were collected in a cross-sectional study among STD clinic attenders in Amsterdam. Seropositivity for HSV-2 was determined in 1798 serum samples by means of a monoclonal antibody-blocking enzyme-linked immunoassay.
history and clinical signs of genital herpes and higher than that among blood donors. 4 In the general US population the prevalence of HSV-2 was higher than previously recognized due to the large percentage of subclinical cases and appeared to have increased in time from 16.4% in 1976-1980 to 21.7% in 1989-1991. 1 ' 7 It is known HSV-2 infection results in a seroconversion and lifelong persistence of antibody which may be used as an objective marker to investigate past sexual behaviour in different populations. Monitoring HSV-2 antibodies may be used to gauge the effect of intervention programmes in age cohorts over time. In a seroepidemiological study in Britain Cowan et al. demonstrated that the presence of antibody to HSV-2 among STD clinic attenders and blood donors had a strong association with gender and past sexual behaviour. 4 In a study among women in New Mexico, US, an association between HSV-2 antibodies and indicators of sexual behaviour was found. 14 Johnson et al. also reported an association with increasing number years of sexual activity. 7 The objectives of the present seroepidemiological study were to determine the prevalence of HSV-2 antibodies in attenders of an STD clinic in Amsterdam, to determine the proportion of individuals with HSV-2 antibodies who had current signs of infection or a history of previous genital herpes, and to investigate the association between demographic variables, lifetime sexual behaviour and HSV-2 antibodies using a HSV type-specific serological test.
Patients and Methods

Study design
This analysis is based on data collected for a study to determine the prevalence of infections with Chlamydia trachomatis among attenders of an STD clinic in Amsterdam in the period [1986] [1987] [1988] . Details of the study design have been presented previously. 1516 Briefly, participants were offered medical examinations and interviews covering demographic characteristics and sexual behaviour: age at first sexual intercourse, sexual orientation, types of sexual contacts (steady, casual, commercial), orogenital or passive anal sexual contact in the past 6 months, numbers of sexual partners and history of STD. During the medical examination a serum sample was taken. If genital ulcerations were present, specimens were collected for culture of HSV. If the patient presented with a recurrent HSV infection, based on medical history and clinical presentation, no specimens were collected. A history of genital herpes was recorded if past episodes of genital herpes were reported by the patient. Contacts of patients with a proven chlamydial or gonococcal infection, who were notified and presented at the STD clinic for examination, were subjected to the same medical examination and interviews. For the present study, serum samples from all participants were used for testing for antibody to HSV-2 following storage at -20°C.
Laboratory methods
Type-specific antibodies to HSV-2 were determined using a monoclonal antibody-blocking enzyme-linked immunoassay. This is a direct modification of the validated monoclonal antibodyblocking radioimmunoassay (Mab block RIA) and shares the same test characteristics.
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Data analysis
Univariate analyses were carried out to examine the association between demographic variables, sexual behaviour and past STD with seropositivity for HSV-2 using the x* test C < 0-05). Number of years of sexual activity and age at Erst intercourse were divided into categories. Multiple logistic regression with seropositivity for HSV-2 as the dependent variable was used to determine independent predictors (P < 0.05). Variables associated univariately were included in the multiple regression models (forwards stepwise selection). The improvement of the model was evaluated with the log-likelihood ratio-test using the X 2 distribution for significance (>95%). As age and years of sexual activity were strongly correlated only the latter was included in the analyses. Separate analyses were carried out for homosexual men, heterosexual men and women and were then compared with the full regression model. In the final multiple logistic regression model for men and women together a variable 'sexual practice per gender' was introduced which is a combination of the variables gender, sexual orientation and receptive anal intercourse. This combined variable weighed the increasing risk for HSV-2 infection with receptive sexual contact.
i.e. anal and (or) vaginal. The association between antibodies to HSV-2, current genital herpes and history of genital herpes was examined. The concordance and discordance in HSV-2 serostatus was studied in known partnerships in the STD clinic population.
Results
Prevalence of HSV-2 antibodies
During the study period 1820 patients enrolled in the study. The participation rate was 83%. Details on non-participation in the study have been reported elsewhere. 15 In summary, for women no differences were found; for men, the non-participants were younger (on average 2 years), were more often foreign nationals (especially Morocco and Turkey), and reported a history of STD less often but had current gonorrhoea more often, compared with the participants."
From 1820 patients 1798 serum samples were available for testing. The presence of HSV-2 antibodies was determined in 1679 STD clinic attenders (580 women, 1099 men) and in 119 contacts of patients with proven chlamydial or gonococcal infection (61 women and 58 men). The overall prevalence of HSV-2 antibodies was 32.3% (542/1679). The prevalence of HSV-2 antibodies was significantly higher among women 42.6% (274/ 580) and homosexual men 40.5% (87/215) than among heterosexual men 23.6% (208/883). The age-spedfic prevalence of HSV-2 antibodies increased consistently with age for heterosexual men (Figure 1) . A similar trend, although less pronounced, was observed for women and homosexual men.
Risk factors univariately associated with HSV-2 antibodies
The results of the univariate analyses indicated a strong association between HSV-2 antibodies and sexual characteristics ( Table 1) . The prevalence of HSV-2 antibodies was lower in Turkish and Moroccan men than that in other ethnic minorities. The highest prevalence among women was found among women from subSaharan Africa and Latin America and, to a lesser extent, from Surinam and the Dutch Antilles. For both sexes, the prevalence of HSV-2 antibodies increased gradually with the numbers of years of sexual activity and with the number of lifetime sexual partners ( Figure 2 ). The prevalence of HSV-2 antibodies was higher among commercial sex workers (CSW) than among non-CSW. The prevalence in CSW from sub-Saharan Africa and Latin America was higher than in non-CSW but not significantly, 91% (20/22) versus 71% (12/17), respectively. Stratified analysis for CSW revealed that only a high number of lifetime partners (>20) was associated with HSV-2 antibodies; increasing age and increasing number of years of sexual activity for CSW were not associated with increasing prevalence of HSV-2 antibodies (data not shown).
There was no apparent association with age at first intercourse, except for a lower prevalence among men with a sexarche of s=20 years. Passive anal contact in the past 6 months was associated (borderline) with HSV-2 antibodies for both men and women with odds ratios (OR) of 1.66 and 1.64, respectively. Also, a history of prior STD was strongly associated with HSV-2 antibodies; this was found consistently for several STD: gonorrhoea, infections with C. trachomatis, syphilis (OR for women: Figure 1 Prevalence of HSV-2 antibodies by age-group, gender and sexual orientation for men. Note the combined agegroup for homosexual men (<24 years) due to low numbers in separate groups urethritis and genital warts for men and salpingitis for women. An increasing number of past gonococcal infections showed a graded association with the prevalence of HSV-2 antibodies. The same was found for an increasing number of chlamydial infections in women (OR none = 1.0; OR lx = 1.59; OR;, 2x = 2.76). The type of last and former sexual partner (casual, steady), the number of partners in the past month or the past 6 months, having had orogenital contact and condom use with casual partners were not associated with HSV-2 antibodies (data not shown).
Independent risk factors for HSV-2 antibodies
In a multiple logistic regression model the following variables remained independently associated with HSV-2 antibodies: female sex, homosexual orientation, receptive anal contact in the past 6 months, increasing number of years of sexual activity and increasing number of lifetime partners, number of past gonococcal infections and country of origin for women. In Table 2 the variables gender, sexual orientation and receptive anal intercourse were combined in the variable 'sexual practice per gender'. The combined variable weighed the increasing risk for HSV-2 infection with receptive sexual contact, i.e. anal and (or) vaginal. Country of origin was included in the model as an interaction effect with gender as it had only a strong association with HSV-2 antibodies for women. In the separate model for heterosexual men, the number of lifetime partners was not independently associated with HSV-2 antibodies anymore; history of gonorrhoea and number of years of sexual activity were the only variables independently associated with HSV-2 antibodies. In the model for homosexual men, the independent association with a large number of lifetime partners was strong (OR 3= 50 partners = 5.72 [95% CI : 1.73-18.88]) but the gradient for increasing years of sexual activity disappeared (data not shown).
HSV-2 antibodies related to a current diagnosis and history of genital herpes
Current genital herpes was diagnosed in 49/1679 (2.9%) of the STD dinic attenders. Forty were diagnosed as primary (or first known) episodes of genital herpes infection; culture results showed that 34 were caused by HSV-2 and six by HSV-1. Of those, 50% (20/40) had serological evidence of HSV-2 infection and may not have been truly primary. Of the first known cases confirmed by culture, presence of HSV-2 antibodies was detected in 19/34 (56%) of HSV-2 infections and 1/6 (17%) of HSV-1 infections. The remaining nine cases were diagnosed as recurrent genital herpes with an HSV-2 seroprevalence of 77.8% (7/9) and no culture was done. Almost 8% (130/1679) of the STD clinic attenders reported a history of genital herpes. Of them, 75% (98/130) had serological evidence of HSV-2 infection (Table 3) . However, of the individuals with HSV-2 antibodies, only 5% had current genital herpes and 18% reported a history of genital herpes.
Prevalence of HSV-2 antibodies in sexual partnerships
The prevalence of antibodies to HSV-2 in known sexual partnerships (n = 119) is shown in seropositive patients had HSV-2 antibodies as well. The latter percentage was higher for steady partners than for casual partners; 52% and 41% respectively. The presence of HSV-2 infection among partners was univariately associated with HSV-2 seropositivity in the index patient (OR = 3.30; 95% CI: 1.45-7.50); the association was stronger for a steady partner (OR = 4.73; 95% CI : 1.69-14.10) than for a casual partner (OR = 1.97; 95% CI : 0.53-7.37). Univariate analyses did not reveal a strong association between HSV-2 antibodies and demographic and sexual characteristics of sexual contacts (data not shown). A gradually increasing association with the number of years of sexual activity and the number of lifetime partners was found but was not significant (due to low numbers). Again, having had passive anal contact in the past 6 months for both women and homosexual men was the only factor univariately (P = 0.001) associated with HSV-2 seropositivity.
Discussion
In this seroepidemiological study (using a validated serological technique) among attenders of an STD clinic in Amsterdam a high prevalence of HSV-2 antibodies was found. Importantly, over 80% of the HSV-2 seropositives did not have a history of genital herpes and 95% had no current clinical signs of infection. The high proportion of unrecognized infection suggests that clinical diagnosis and reported history of genital herpes cannot identify the majority of the individuals with past HSV-2 infection. Another important outcome of this study is that the presence of HSV-2 antibodies has a strong graded association with past sexual behaviour (more specifically, number of lifetime partners, number of gonococcal infections and number of years of sexual activity) and may therefore be used as a surrogate marker for sexual risk behaviour. Moreover, HSV-2 antibodies appear to be independently associated with receptive anal intercourse. The prevalence of HSV-2 antibodies in this population was higher in women and homosexual men than in heterosexual men, after controlling for country of origin, number of lifetime sexual partners and number of years of sexual activity. A high prevalence among women was also found among STD clinic attenders in London and Seattle 4 ' 9 and in a population-based survey on AIDS in San Francisco.
3 Also, a large proportion of them did not have a history of genital herpes.
3 ' 4 ' 9 ' 14 The higher prevalence rates among women could be due to increased efficiency in transmission of HSV from male to female than from female to male, as was suggested by empirical evidence by Mertz 10 (which has also been observed for other STD). In the present study, receptive anal intercourse was identified as an independent risk factor for the presence of HSV-2 antibodies, not only for homosexual men but also for women. The combined variable 'sexual practice per gender' (e.g. homosexual men with or without receptive anal intercourse and women with or without anal intercourse versus heterosexual men) elucidated the ranking risk associated with receptive sexual contact, either through vaginal or anal intercourse.
Consistent with other studies, the seroprevalence of HSV-2 increased gradually with age and number of years of sexual activity as HSV-2 antibodies are most often acquired after the onset of sexual activity. 2^*14 Our data, as those of Cowan etal., 4 did not show an apparent association with young age at first intercourse as was reported (without controlling for potential confounding factors) by Becker. 14 The seroprevalence in our study was independently associated with increasing numbers of lifetime sexual partners as has been observed by others. 2^1 ' The association with number of partners was less strong for heterosexual men than for homosexual men and women. The association with commercial sex work for women disappeared after controlling for the number of partners and other potentially confounding variables. A history of any STD was found to be predictive for seropositivity with an apparent ranking for number of past (gonococcal) infections.
For men, country of origin was not significantly associated with HSV-2 antibodies. For women, there were marked differences: women born in Surinam, Dutch Antilles, sub-Saharan Africa and Latin America had the highest prevalence of HSV-2 antibodies. Because almost a third of the foreign-bom women reported an 'unknown number of partners' the association could not be further studied. However, the high HSV-2 seroprevalence in the category unknown suggests rather a high number of sexual partners than a truly unknown number. The association of HSV-2 antibody and country of origin may also reflect the sexual contacts of the male partners which may differ per country. An independent correlation between HSV-2 seroprevalence and ethnicity (blacks, Hispanics in the US) was also demonstrated for women in a population-based study. 3 In a large nationwide survey in the US the high prevalence among blacks was related to longer periods of being unmarried and of sexual activity. 7 However, in gynaecology patients in New Mexico the presence of HSV-2 antibodies appeared not to be associated with Hispanic ethnicity.
14 Our independent association with country of origin for women could be due to a higher overall prevalence of HSV-2 infection in the native countries, as was shown for several countries, 2 or to other factors which we were unable to identify and to control for (i.e. like sexual contacts of partners).
In the present study we were able to compare the serostatus in known partnerships. The overall serostatus in sexual partners was comparable with that in the general population of STD dinic attenders. The prevalence of HSV-2 antibodies appeared to be higher in partners of HSV-2 seropositive patients than in those of seronegative patients. Although details on the length of the relationship were not available, the seroprevalence in steady partners was higher than that in casual partners. It may reflect a higher transmission rate in steady ongoing sexual relationships than in casual sexual contacts. It could also indicate that patients and their partners have similar sexual lifestyles although no apparent association between sexual determinants and seroprevalence in partners could be found apart from receptive anal intercourse.
The type-specific serological test used in this study (Mab block enzyme-linked immunoassay) was shown to be less sensitive in detecting HSV-2 antibodies from HSV-2 primary episodes in comparison with the Western blot assay; 76% (16/21 sera) versus 91% (19/21 sera) respectively. 17 Both the Western blot and the Mab block RLA were similarly effective (96%) in detecting HSV-2 antibodies in sera from recurrent HSV-2 infections. 17 Although the interval between the onset of primary symptoms and bleed was not available in this study, a low sensitivity in detecting type-specific antibody (56%) among primary episodes of genital herpes was observed. This is related to the natural history of HSV infection where type-common humoral responses precede type-specific antibody production following primary episode infection. 13 ' 18 The underestimate of HSV-2 seroprevalence in primary episode infection may influence our results. However, the observed associations appear not to be affected if individuals with a primary episode of HSV-2 infeCTion but no serological evidence were included as seropositives in our analyses.
Identification of HSV-2 infected individuals requires antibody testing. Non-serological methods, like reported history of genital herpes and clinical evaluation, are poor predictors of HSV-2 infection. 9 Asymptomatically infected individuals constitute a large reservoir of HSV-2 and may further spread the disease to their sexual partners. The effect of counselling individuals with antibody to HSV-2 (but no history of genital herpes) has been suggested as an effective approach to limit the spread of genital herpes; 12 -19 clinical reactivation of genital herpes was recognized more easily and this could help to reduce further transmission of genital herpes. Although a high percentage of transmission results from sexual contact during periods of asymptomatic (or subclinical) viral shedding it was also shown that transmission is not inevitable in couples with a long-lasting sexual relationship. 1020 The latter is suggested by our study as well with 28% discordant serostatus among steady partnerships.
Results from this study are based on data collected in 1986-1988 and behavioural changes in the STD clinic population may have occurred since then. At that time, massive behavioural changes as a response to AIDS had occurred already, as previously shown by declining gonorrhoea rates among homosexual men. 21 The prevalence rates of genital herpes among STD clinic attenders have been increasing in the past decade. But actual information is missing which would determine whether present correlates for HSV-2 seroprevalence are different or similar compared with those in 1986-1988. However, results from this study can be used as baseline prevalence data for STD clinic populations in the Netherlands. Future surveys on HSV-2 seroprevalence in the STD clinic population and the general population are needed to further assess the value of HSV-2 seroprevalence data.
In conclusion, with the use of a type-specific serological test we found a high prevalence of HSV-2 infections among STD clinic attenders in Amsterdam. Most of the seropositives had an unrecognized or asymptomatic HSV-2 infeCTion and were unaware of the infeCTion. We also found a strong graded association with past sexual behaviour, indicating that HSV-2 seropositivity could be used as a serological marker for sexual lifestyle to compare populations over time.
